Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Tumor necrosis factor antagonists

Keywords Azathioprine methotrexate pharmacogenetics polymorphisms rhen-matoid arthritis sulfasalazine tumor necrosis factor antagonists. [Pg.413]

Ranganathan, P. (2005) Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis. Pharmacogenomics. 2, 279-282. [Pg.436]

For rheumatoid arthritis, the pharmacogenomics of three major diseasemodifying antirhenmatic drags (methotrexate, azathioprine, and sulfasalazine) and one class of biologic antirhenmatic drags (the tumor necrosis factor antagonists) are discnssed in detail. [Pg.495]

Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003 138 807-11. [Pg.385]

Peyrin-Biroulet L et al Efficacy and safety of tumor necrosis factor antagonists in Crohn s disease Meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008 6 644. [PMID 18550004]... [Pg.1338]

Kawai A, Kawai M, Murata Y, Takada J, Sakakibara M (1998) Preparation of pyridylpyr-roles as interleukin and tumor necrosis factor antagonists. PCT Int Appl. CODEN PIXXD2 WO 9802430 A1 19980122, p 95... [Pg.91]

Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum... [Pg.1282]

Sulfasalazine, Tumor necrosis factor antagonists, Rituximab, Tocilizumab... [Pg.625]

This chapter highlights some of the recent, major publications in the field of pharmacogenetics in RA and describes the implications of this field for future research and clinical care. The pharmacogenetics of three major non-biologic DMARDs, methotrexate (MTX), azathioprine, and sulfasalazine (SSZ), and three biologic DMARDs, the tumor necrosis factor antagonists, rituximab, and tocilizumab in RA, is reviewed. [Pg.625]

Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 2007 27(4) 399-413. [Pg.75]

Gomez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007 57(5) 756-761. [Pg.75]

Mossner R, Schon MP, Reich K. Tumor necrosis factor antagonists in the therapy of psoriasis. Qin Dermatol 2008 26(5) 486-502. [Pg.800]

Tumor necrosis factor antagonists, infection risk, 29.395, 31.594... [Pg.1121]

AIDS, polio vaccine, 23.352 AIDS, transfusions, 12.298 necrotizing fasciitis, NSAIDs, 28.121 total parenteral nutrition, 22.379 tumor necrosis factor antagonists, 29.395, 31.594... [Pg.1125]

Rigby WF. Drug insight different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior Nat Clin Pract Rheumatol 2(X)7 3 ... [Pg.157]

Furst DE, Wallis R, Broder M, et al. Tumor necrosis factor antagonists different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006 36 159 167. [Pg.157]

Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004 38 1261-1265. [Pg.158]

S Ataquimast, Tinamast U Tumor necrosis factor antagonist (P.581)... [Pg.8]

See other pages where Tumor necrosis factor antagonists is mentioned: [Pg.874]    [Pg.425]    [Pg.465]    [Pg.641]    [Pg.598]    [Pg.621]    [Pg.780]    [Pg.31]   
See also in sourсe #XX -- [ Pg.425 ]



SEARCH



Tumor necrosis

Tumor necrosis factor

Tumor necrosis factor antagonists rheumatoid arthritis

Tumor necrosis factor antagonists, infection risk

© 2024 chempedia.info